Imatinib-d 4

Overview

Imatinib-d 4 (STI571-d 4 ) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > c-Kit | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-15463S1
• CAS No.: 1134803-16-9
• Molecular Formula: C29H27D4N7O
• Molecular Weight: 497.63
• Purity: 99.82%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source